Dr. Grupp Discusses the Findings of the ELIANA Trial

Stephan Grupp, MD, PhD
Published: Monday, Dec 17, 2018



Stephan Grupp, MD, PhD, director, Cancer Immunotherapy Program, director, Translational Research for the Center for Childhood Cancer Research, medical director, Stem Cell Laboratory, Children’s Hospital of Philadelphia, discusses the findings of the ELIANA trial.

Updated findings from the phase II ELIANA study of tisagenlecleucel (Kymriah) in pediatric and young adult patients with relapsed or refractory acute lymphoblastic leukemia (ALL) were presented at the 2018 ASH Annual Meeting. In this population, the CD19-targeted chimeric antigen receptor (CAR) T-cell therapy demonstrated sustained rates of relapse-free survival (RFS) and overall survival (OS) at 24 and 18 months.

The 24-month RFS rate with tisagenlecleucel was 62% (95% CI, 47%-75%). At months 12 and 18, the RFS rate was 66% (95% CI, 52%-77%). Additionally, the 12-month OS rate was 76% (95% CI, 65%-85%) with tisagenlecleucel and the 18-month OS rate was 70% (95% CI, 58%-79%). These pediatric and young adult patients had a high disease burden with overtly relapsed ALL, Grupp notes. The updated results show that these patients are staying in remission for a significant amount of time following infusion of this CAR T-cell therapy.
SELECTED
LANGUAGE


Stephan Grupp, MD, PhD, director, Cancer Immunotherapy Program, director, Translational Research for the Center for Childhood Cancer Research, medical director, Stem Cell Laboratory, Children’s Hospital of Philadelphia, discusses the findings of the ELIANA trial.

Updated findings from the phase II ELIANA study of tisagenlecleucel (Kymriah) in pediatric and young adult patients with relapsed or refractory acute lymphoblastic leukemia (ALL) were presented at the 2018 ASH Annual Meeting. In this population, the CD19-targeted chimeric antigen receptor (CAR) T-cell therapy demonstrated sustained rates of relapse-free survival (RFS) and overall survival (OS) at 24 and 18 months.

The 24-month RFS rate with tisagenlecleucel was 62% (95% CI, 47%-75%). At months 12 and 18, the RFS rate was 66% (95% CI, 52%-77%). Additionally, the 12-month OS rate was 76% (95% CI, 65%-85%) with tisagenlecleucel and the 18-month OS rate was 70% (95% CI, 58%-79%). These pediatric and young adult patients had a high disease burden with overtly relapsed ALL, Grupp notes. The updated results show that these patients are staying in remission for a significant amount of time following infusion of this CAR T-cell therapy.

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Medical Crossfire®: How to Use Liquid Biopsies Throughout the Lung Cancer Treatment Continuum OnlineJan 31, 20191.5
Community Practice Connections™: Current Status and the Future Potential of CAR T-Cell Therapy for Lymphoid Malignancies: The Experts Weigh-In on Recent Data and Clinical ExperienceJan 31, 20192.0
Publication Bottom Border
Border Publication
x